Clinical trials: Metastatic Triple-negative Breast Cancer
Triple Negative Metastatic Breast Cancer, BRCA-mutated Solid Tumor
Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer
Open label, non-randomized, dose escalation and expansion Phase Ia/b trial to evaluate the safety of the combination of BMN 673 and carboplatin, and subsequently BMN 673 in combination with paclitaxel and carboplatin to determine…
- Trial name
- NCT02358200
- Testing
- BMN-673, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Pamela Munster
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with binimetinib in treating patients with solid tumors that carry RAS alterations and that have spread to other places in the body…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma
- Trial name
- NCT05111561
- Testing
- BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
This phase II trial tests how well radiation therapy with pembrolizumab and chemotherapy (paclitaxel or nab-paclitaxel or carboplatin and gemcitabine) works in treating patients with PD-L1 positive triple negative breast cancer…
- Trial name
- NCT06492759
- Testing
- Radiation Therapy, Pembrolizumab, Nab-paclitaxel
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Emory University
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
This phase I trial studies the side effects and best dose of veliparib when given together with cisplatin and vinorelbine ditartrate in treating patients with breast cancer that has returned or spread to other parts of the body.
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Hereditary Breast/Ovarian Cancer - BRCA1, Hereditary Breast/Ovarian Cancer - BRCA2
- Trial name
- NCT01104259
- Testing
- veliparib, cisplatin, vinorelbine tartrate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Estrogen Receptor Negative, HER2/Neu Negative
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
This is a Phase II treatment study that is done to evaluate how effective and safe the combination of pembrolizumab and cisplatin work in treating participants with triple-negative breast cancer that had spread to other parts of…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Breast Cancer, Progesterone Receptor Negative
- Trial name
- NCT03644589
- Testing
- Pembrolizumab, Cisplatin
- Where
- United States
- Sponsor
- University of Washington
Triple Negative Breast Cancer, Non-Metastatic
Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy
This clinical study aims to determine if skipping breast and axillary surgery could provide similar control of local and distant disease, with fewer complications and better quality of life, for triple-negative breast cancer…
- Trial name
- OMICHIR (NCT07357948)
- Testing
- Omission of surgery
- Where
- 4 sites in France
- Volunteers
- 150 people
- Sponsor
- Institut Curie
Triple Negative Breast Cancer, Metastatic Breast Cancer
Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
The goal of this clinical trial is to evaluate the efficacy of investigator's choice of chemotherapy, either alone or in combination with everolimus, in treating patients with locally recurrent inoperable or metastatic…
- Conditions
- Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation
- Trial name
- BCTOP-T-M03 (NCT05954442)
- Testing
- Everolimus, Investigator's Choice of Chemotherapy
- Where
- China
- Volunteers
- 203 people
- Sponsor
- Fudan University
Triple Negative Breast Cancer (TNBC), Metastatic Breast Cancer
JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
This is a prospective, open-label, randomized phase II clinical study which recruits unresectable recurrent or metastatic triple-negative breast cancer resistant to immunotherapy.
- Trial name
- NCT06731153
- Testing
- Ivarmacitinib, Camrelizumab (SHR-1210), Eribulin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Triple-negative Breast Cancer
Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer
To compare the therapeutic effect of vinorelbine used alone or combined with apatinib mesylate for recurrent or metastatic TNBC patients who have at least received one chemotherapy regimen, including anthracyclines and taxanes…
- Trial name
- NCT03932526
- Testing
- Vinorelbine + Apatinib
- Volunteers
- 184 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Triple-Negative Breast Cancer
T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients
This is an open-label, single-arm phase II trial of first-line treatment with trastuzumab deruxtecan (T-DXd) for patients with locally advanced or metastatic triple-negative breast cancer, luminal androgen receptor subtype…
- Trial name
- NCT05953168
- Testing
- Trastuzumab Deruxtecan
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Fudan University
Triple Negative Breast Cancer
Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer
The purpose of this study is to assess the efficacy and safety of Cadonilimab (AK104) plus Eribulin compared to the efficacy and safety of Eribulin monotherapy in the treatment of adult patients with recurrent, or metastatic…
- Trial name
- NCT06202313
- Testing
- Cadonilimab, Eribulin
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Shengjing Hospital
Breast Cancer
BKM120 For Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) has an aggressive phenotype and poor prognosis. This tumor type characterized by lack of expression of estrogen receptor (ER), progesterone receptor (PR) and no amplification of the human…
- Trial name
- NCT01790932
- Testing
- BKM120
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Triple Negative Breast Cancer
A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer
This is an open-label, single arm, multi-stage, phase II trial of Trifluridine/tipiracil as a palliative treatment for patients with metastatic triple negative breast cancer who have failed both a taxane and anthracycline or have…
- Trial name
- TACTIC (NCT04149444)
- Testing
- Trifluridine/Tipiracil
- Where
- Canada
- Sponsor
- AHS Cancer Control Alberta
Metastatic Triple Negative Breast Cancer, Metastatic Testicular Cancer
The TASTY-steering Study
This is a multicentre non-blinded randomised intervention trial with a parallel cluster design. The multicentre study will be performed at 12 hospitals in the Netherlands.
- Conditions
- Metastatic Triple Negative Breast Cancer, Metastatic Testicular Cancer, Stage II-IV Diffuse Large B Cell Lymphoma
- Trial name
- TASTY-steering (NCT07258563)
- Testing
- Taste steering
- Where
- 11 sites in Netherlands
- Volunteers
- 201 people
- Sponsor
- University Medical Center Groningen
Breast Cancer
Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)
The main purpose of this study is to see whether the combination of selinexor (KPT-330) can help people with triple negative breast cancer (TNBC).
- Trial name
- NCT02402764
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Triple Negative Breast Cancer, Natural Killer Cells
A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation.
The purpose of this research study is: To test blood for the presence of tumor derived circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) using an investigational medical device called the LiquidBiopsy®.
- Conditions
- Triple Negative Breast Cancer, Natural Killer Cells, BRCA Mutation
- Trial name
- NCT02639832
- Testing
- LiquidBiopsy®, NK VueTM
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Cynvenio Biosystems
Metastatic Triple Negative Breast Cancer
Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
This study will evaluate the effectiveness and safety of the combination of two drugs, Veliparib and Lapatinib, given to participants with metastatic triple negative breast cancer that have undergone previous treatment.
- Trial name
- NCT02158507
- Testing
- Combination of Veliparib + Lapatinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Locally Advanced or Metastatic Solid Tumors
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
The primary objective of this study was to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2…
- Trial name
- NCT03150810
- Testing
- Pamiparib, Temozolomide
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 139 people
- Sponsor
- BeiGene
Metastatic Breast Cancer
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
The purpose of the Phase 1b portion of the study is to determine the best dose of PLX3397 when given in combination with standard dose eribulin (Halaven™).
- Trial name
- NCT01596751
- Testing
- PLX3397, Eribulin
- Where
- 3 sites in United States
- Volunteers
- 67 people
- Sponsor
- Hope Rugo, MD
Metastatic Breast Cancer
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
The purpose of this research study is to look at the effectiveness of a combination of doxil, carboplatin and bevacizumab on metastatic breast cancer.
- Trial name
- NCT00608972
- Testing
- Doxil, Carboplatin, Bevacizumab
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Rutgers, The State University of New Jersey